Statins can be differentiated into two types, based on their solubility, which have potentially differing effects on the coronary artery wall. However, suspected differences in statins' effects on plaque composition have not been systemically investigated.
M
any clinical trials of serial intravascular ultrasound (IVUS) examinations showed that statin therapy could reduce coronary plaque volume. [1] [2] [3] Therapy for lowering low-density lipoproteincholesterol (LDL-C) levels improved plaque stability and endothelial function, and even caused plaque regression. 4) Recent developments in the ultrasound imaging technology known as integrated backscatter (IB)-IVUS have enabled the classification of the tissue characteristics of a coronary plaque. Captured images have correlated highly with pathological findings. 5, 6) Plaque stability can potentially be achieved by a change in plaque contents, such as the removal of lipids from the lipid-rich plaque and an increase in its fibrous tissue, without an improvement in the degree of plaque volume. 7) Using serial IVUS examinations in patients with stable angina pectoris, the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin (SATURN) trial revealed that water-soluble and lipid-soluble statins provided comparable benefits in reducing plaque volume. 8) These statins have different chemical structures and show differences in their cell-membrane permeability. We have previously reported that the lipid-soluble statin atorvastatin increased microRNA let-7i and decreased Toll-like receptor-4 levels in patients with coronary artery disease (CAD). 9) In this paper, we reveal differences between water-and lipidsoluble statins in their effects on nonculprit coronary atherosclerosis and plaque composition in patients with acute coronary syndrome (ACS), with the view to assessing their clinical efficacy.
Methods
Patients and study design: The Atorvastatin versus Rosuvastatin in Patients with Acute Coronary Syndrome (ATRAS) study described herein was a simple, random- Ishikawa, ET AL ized, open-label, parallel-group, single-center study to examine the effect of treatment with atorvastatin versus rosuvastatin in Japanese patients with ACS.
The study population consisted of ACS patients who had undergone percutaneous coronary intervention (PCI) following IVUS examination, including tissue analysis with IB-IVUS, between December 2008 and August 2011. Eligible patient characteristics included being over 20 years of age and having a serum LDL-C level !100 mg/ dL for hyperlipidemia without treatment, according to American Heart Association (AHA) 2002 guidelines (Adult Treatment Panel III). 10) Patients with cardiac shock, familial hyperlipidemia, uncontrolled liver dysfunction, a thyroid disorder, the presence of malignancy, or severe coronary calcification lesions were excluded. A patient with ACS was defined as having at least two of the following criteria: ischemic symptoms and signs, evidence of coronary ischemia from electrocardiography findings, elevation of serum creatinine phosphokinase levels, or a positive troponin T test. Follow-up coronary angiography and an IVUS examination were performed between 6 and 12 months after PCI. Any blood examinations for lipid levels were performed with the patient under fasting conditions. LDL-C levels were calculated using Friedewald's method. 11) For ethical reasons, we did not have a control group of patients who did not receive statin therapy. The end-point was defined as follows: 1) a percentage change in blood lipid profiles; 2) a percentage change of coronary plaque volume on grayscale IVUS; 3) changes found in tissue characteristics of the plaque after IB-IVUS examination; and 4) cases of death of all causes, hospitalization by all causes of a cardiovascular event, and repeat revascularization. Patients were randomized to one of two groups: atorvastatin (10 mg/day) or rosuvastatin (2.5 mg/ day) within 48 h after PCI. Randomization was stratified using a table of random numbers. Atorvastatin was chosen from among lipid-soluble statins because it is the most commonly prescribed of this family of medications used to treat hyperlipidemia in Japan. Rosuvastatin was chosen from among water-soluble statins since a previous study reported that atorvastatin (10 mg/day) and rosuvastatin (2.5 mg/day) demonstrated equal effects on LDL-C levels. 12, 13) The protocol used was approved by the ethics committee of Iwate Medical University Hospital and registered at UMIN (ID: 000004200). Written informed consent was obtained from all enrolled patients. IVUS procedure and imaging: An IVUS examination was conducted at baseline and at follow-up. After coronary stents were successfully deployed in culprit lesions of ACS patients, a final IVUS examination was carried out using a commercially available system (AtrantisTM SR Pro2, 40 MHz; Boston Scientific, Marlborough, MA, USA). An IVUS catheter was advanced into the target vessel and the transducer positioned as distally as possible to the target lesion. The transducer was pulled back by a motor device at a speed of 0.5 mm/s and images were captured. All IVUS studies were performed immediately after the intracoronary administration of nitroglycerin to prevent coronary spasm. The console used was a Galaxy2 system (Boston Scientific). After statin therapy, an IVUS examination was repeated in the same coronary artery using the same type of IVUS catheter as used at baseline. IVUS measurements: Images obtained were analyzed by an experienced doctor and technician in a blind fashion regarding patient characteristics, imaging date, and baseline or follow-up examination status. The width of each analyzed lesion of interest for IVUS analysis was 4 to 10 mm. To ensure that the same anatomical lesion was analyzed at baseline and follow-up, a stent edge, side branch, left circumflex artery, and calcification of the coronary artery were used as anatomical landmarks. To exclude the influence of PCI, the site of examination was at least 3 mm away from the stent's edge. Lesion analyses were performed using Echo Plaque-2 system measurement software (Indec, Co, Ltd, Santa Clara, CA, USA). IVUS tracing was performed according to the guidelines of the American College of Cardiology (ACC) and the European Society of Cardiology. 14) A trace of both the lumen and the plaque interface was performed for every 0.27 mm interval of frames; other measurements were carried out semi-automatically. The plaque cross-sectional area (CSA) was calculated by subtracting the external elastic membrane (EEM) CSA from the lumen CSA. To compute a sum of the plaque area, the following formula was used: plaque volume = Σ (EEM CSA -lumen CSA). The absolute value of plaque volume changes was set to a primary end-point in a grayscale IVUS study.
An IB-IVUS system (YD Corporation, Nara, Japan) was used as previously described. 6, 15, 16) The system was connected to a conventional IVUS imaging system, and a radiofrequency signal output was acquired. IB-IVUS images were obtained at the same time as conventional IVUS measurements after PCI. A measurement part of plaque volume (length and section) measured the same part of the conventional IVUS. IB-IVUS images were captured at intervals of 1 mm and measured for a maximum of 10 slices. Coronary plaque tissue was characterized by classification into four groups, lipid pool, fibrous tissue, dense fibrous tissue, or calcification, according to differences in IB.
17) The area of each tissue characterization (mm 2 ) was obtained from the multiplication of plaque CSA and the % tissue characterization volume; we assumed its volume (mm 3 ) per 1 mm in length and found the volume (mm 3 ) of the sum that traced and calculated each organizational area. Changes in these volumes were compared between atorvastatin and rosuvastatin groups. Statistical analysis: Continuous variables are expressed as mean ± standard deviation (SD). Comparisons of continuous variables between the two groups were performed by a two sample t-test or Mann-Whitney U test, and those between parameters' baseline and follow-up were performed by a one-sample t-test. Comparisons of categorical values between the two groups were performed with a chi-square test. Statistical analyses were performed using SPSS Ver.21 software (SPSS Inc., Chicago, IL, USA) for Windows. A P value of < 0.05 was considered statistically significant. tients were randomly assigned to receive atorvastatin, and 30 patients were randomly assigned to receive rosuvastatin. Figure 1 presents the study design and the patient analytical set. In the atorvastatin group, 11 patients did not have analyzable IVUS images, seven patients withdrew consent, and one patient was withdrawn for druginduced liver dysfunction. A total of 18 patients in this group completed the trial. In the rosuvastatin group, seven patients did not have analyzable IVUS images, five patients withdrew consent, and one patient was lost to follow-up. A total of 17 patients in this group completed the trial. The median follow-up period with the interquartile range was 7.3 ± 1.6 months for the atorvastatin group and 7.8 ± 2.3 months for the rosuvastatin group, respectively. Baseline patient characteristics and laboratory data for the two groups are shown in Table I . Patients in the rosuvastatin group were slightly and significantly older than those in the atorvastatin group. There were no significant differences in gender, coronary risk factors, CAD status, target vessel, ejection fraction, treatment allocation, and baseline HbA1c and creatinine levels between patients in the atorvastatin and rosuvastatin groups. White blood cell counts were markedly increased at baseline and did not differ between the two groups. Lipid profiles: Table II summarizes changes in serum lipid profiles. The mean LDL-C concentration decreased from 138.1 ± 32.9 mg/dL at baseline to 80.8 ± 23.1 mg/ dL at follow-up (P < 0.001) in the atorvastatin group and from 136.3 ± 34.1 mg/dL to 82.0 ± 25.8 mg/dL (P < 0.001) in the rosuvastatin group during the study period. There were no significant differences in percentage changes of LDL-C levels from baseline to follow-up between the atorvastatin and rosuvastatin groups. Highdensity lipoprotein-cholesterol seemed to be higher at follow-up than at baseline (46.8 ± 12.4 mg/dL to 51.3 ± 14.4 mg/dL and 45.7 ± 9.3 mg/dL to 49.5 ± 7.9 mg/dL for atorvastatin and rosuvastatin groups, respectively), but Ishikawa, ET AL 3 ) 33.8 ± 20.0 29.6 ± 13.6 0.47 Lipid pool (mm 3 ) 36.0 ± 19.5 34.9 ± 20.4 0.87 these differences were not significant (Table II) .
Results

Patient characteristics:
Grayscale IVUS results:
There was no significant difference in the mean length measurement between the atorvastatin (8.6 ± 2.4 mm) and rosuvastatin (9.4 ± 1.7 mm; P = 0.26) groups. Grayscale IVUS changes in findings from baseline to follow-up are shown in Table III 
IB-IVUS results:
There were no significant differences between the two treatment groups with regard to the volumes of the lipid pool, fibrous tissue, dense fibrous, and calcification at baseline (Table IV) . The plaque volume showed a significant reduction from 74.0 ± 37.7 mm 3 to 65.2 ± 37.8 mm 3 (P < 0.05) in the atorvastatin group and from 67.6 ± 30.8 mm 3 to 58.3 ± 22.1 mm 3 (P < 0.01) in the rosuvastatin group from baseline to follow-up. There were no significant changes in the volume of the lipid pool from baseline to follow-up: 36.1 ± 19.5 mm 3 to 34.7 ± 24.2 mm 3 in the atorvastatin group and from 34.9 ± 20.4 mm 3 to 30.4 ± 16.2 mm 3 in the rosuvastatin group. On the other hand, fibrous tissue volume at follow-up significantly decreased in both groups compared with baseline, from 33.8 ± 20.0 mm 3 to 27.5 ± 14.9 mm 3 (P < 0.01) for the atorvastatin group and from 29.6 ± 13.6 mm 3 to 24.8 ± 7.6 mm 3 (P < 0.05; Figure 2 ) for the rosuvastatin group. However, there were no significant differences in the percentages of components in the coronary artery plaque and mean changes in plaque components compared with baseline and follow-up (Table V, Figure 3) . Additionally, we could not identify significant correlations between changes in LDL-C levels and not only plaque volumes but also relative-percentage lipid pool compositions in this small sample. The intra-and inter-observer correlation coefficients were 0.90 (95% CI 0.80-0.95) and 0.77 (95% CI 0.56-0.88), respectively. Figure 2 . Changes in plaque components at baseline and follow-up. Atorvastatin: P = 0.005 for plaque volume, P = 0.03 for calcification, P = 0.05 for dense fibrous, P = 0.004 for fibrous tissue, and P = 0.65 for lipid pool. Rosuvastatin: P = 0.007 for plaque volume, P = 0.63 for calcification, P = 0.92 for dense fibrous, P = 0.04 for fibrous tissue, and P = 0.08 for lipid pool. Clinical outcomes: Neither cases of all-death nor hospitalization by causes of all cardiovascular events occurred until follow-up. As for repeat revascularization, four cases occurred in the atorvastatin group and two cases in the rosuvastatin group; a significant difference was not observed between them (P = 0.41).
STATIN SOLUBILITY AND CORONARY PLAQUES
Discussion
We compared the impact of rosuvastatin and atorvastatin, as determined by IB-IVUS, on plaque volume and composition of non-infarct-related lesions in patients with ACS. We did not observe significant differences in terms of the reduction of plaque volume when treating patients with water-and lipid-soluble statins. Moreover, the regression in plaque volume observed between baseline and follow-up for both statins was attributed to a decrease in the mainly fibrotic components of plaques. In terms of doses of these agents, 10 mg of atorvastatin appeared to have almost similar effects to 2.5 mg of rosuvastatin regarding a reduction in serum LDL-C levels, as well as a reduction of plaque volume. Statin doses and plaque volume changes: Similar to the present study, a number of prospective studies have investigated the effects of atorvastatin and rosuvastatin on the regression of coronary artery plaques in Japanese patients with ACS. The ESTABLISH study described how 20 mg/ day of atorvastatin caused LDL-C levels to decrease by 41.7% and plaque volumes to regress by 13.1%. 18) Furthermore, the ELAN study showed that 2.5-5 mg/day of rosuvastatin caused LDL-C levels to decrease by 38% and plaque volumes to regress by 18%. 19) Similarly, we showed that atorvastatin and rosuvastatin caused LDL-C levels to decrease by 41.2% and 38.8%, respectively. Although both statins were taken in low doses by patients, the LDL-reducing effects observed by us were similar to those induced by higher doses. We also found that plaque volumes regressed by 8.0% and 6.9% with atorvastatin Ishikawa, ET AL Figure 3 . Mean changes in plaque components in the atorvastatin and rosuvastatin groups. P = 0.88 for plaque volume, P = 0.08 for calcification, P = 0.11 for dense fibrous, P = 0.58 for fibrous tissue, P = 0.41 for lipid pool.
and rosuvastatin, respectively. These regression rates were lower than those seen in previous studies and may be because the statin doses used in our study were lower than those used by others. While the LDL-C management target values in Europe and Japan are based on the "the lower, the better" concept, the 2013 ACC/AHA guidelines establish a policy based on "Fire and Forget," with no absolute LDL-C value set as a target lipid value. 20) While we noted adequate reductions in LDL-C levels, even with low doses of statins, plaque regressions, however, were inferior to those obtained in other studies using higher statin doses. This suggests that the statin dose is related to plaque regression, and we speculate that factors other than reductions in LDL-C levels are involved. We believe that a new index, other than absolute LDL-C values, is therefore required when setting statin doses for the secondary prevention of ACS. Plaque components contributed to plaque regression: Changes in coronary plaque components induced by statins measured using imaging modalities have been examined in various studies. Using virtual histology (VH)-IVUS, the TRUTH study reported that fibrous plaques regressed more in patients in whom statin treatment led to the regression of coronary plaque than in those in whom this increased. 21) Moreover, in an investigation of changes in plaque components using IB-IVUS in patients with stable angina pectoris, Kawasaki, et al. 7) reported that the internal administration of atorvastatin (20 mg) could cause plaque lipid components to be replaced by fibrous components. We demonstrated that statin treatment caused reductions in fibrous components, in contrast to findings of previous reports. Statins have been shown to have a beneficial effect on reducing fibrosis in chronic hepatitis and fibrosis of the kidney, 22, 23) suggesting that statins may reduce fibrotic components of coronary plaques by similar a mechanism. A significant reduction of the lipid pool may also have been found if we had the opportunity to study more cases, since our sample size was limited. Since the mechanism for plaque regression appears to be complex and involve factors other than the reduction of LDL-C levels caused by statins, we believe that further research is required to clarify our results. Water-soluble and lipid-soluble statins: Statins can be divided into two groups: water-and lipid-soluble statins. Regarding the difference in pharmacological action between water-and lipid-soluble statins, the cell-membrane permeability of lipid-soluble statins is thought to be superior to that of water-soluble statins. 24) A previous study evaluated the difference in effect on acute myocardial infarction patients between pravastatin and atorvastatin. This study indicated that pravastatin, a water-soluble statin, would be more effective in protecting heart and kidneys than atorvastatin, a lipid-soluble statin. 25) In animal models, lipid-soluble statins enhanced myocardial stunning, in conjunction with adenosine triphosphate reduction, after ischemia. 26) Furthermore, atorvastatin increased the number of CD4+CD25+FOXP3+ Tregs that may play an atheroprotective role during the development of atherosclerosis in patients with ACS. 27) On the other hand, another report showed that, in patients with acute myocardial infarction, a significant difference was not seen between lipid-soluble and water-soluble statins 1 year after treatment; nevertheless, of the two statin types, greater numbers of major adverse cardiac events were noted in the water-soluble statins group at 1-and 6-month clinical follow-ups. 28) Because lovastatin, a lipid-soluble statin, can induce the apoptosis of fibroblasts both in vivo and in vitro, 29) it is possible that treatment with lipid-soluble statins would be the cause of a decrease in fiber ingredients. In the current study, we noted no significant differences between lipidand water-soluble statins in decreasing non-target plaque volumes, as well as in changing plaque components. Any differences in potential pharmacological actions between both statins may not be substantial in a clinical setting. Study limitations: There are several study limitations. Firstly, the number of patients studied was small. Further study in the future is needed for a larger patient cohort. Secondly, IVUS image analysis was not possible for a several number of enrolled patients. Thirdly, the area of calcification appeared significantly decreased in follow-up comparisons with baseline findings in the atorvastatin group. However, it is thought that operator error can be easily introduced when tracing the plaque interface in IB-IVUS images, because calcification covers such a small area. Another limitation to consider is that it is possible that thrombi in coronary arteries may have influenced the IVUS images because we focused on ACS cases in our study. In addition, we could not exclude the possibility of an effect on the plaque of the stent itself, because there were several cases where the distance from the measurement position of the plaque to the stent edge was less than 5 mm, which is thought a little too close to measure. Finally, we did not use other imaging modalities normally used for the assessment of tissue characteristics: VH-IVUS, optical coherence tomography, and i-Map systems.
Conclusions
The effects of water-soluble and lipid-soluble statins on changes in coronary plaque volume and composition may be similar. Further investigation is needed to clarify the difference in the effects of water-and lipid-soluble statins on plaque components.
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